Quick-Med Technologies Presenting at Prestigious SAWC/WHS Conference

GAINESVILLE, Florida, April 8, 2008 – Quick-Med Technologies, Inc. announced today that Bernd Liesenfeld, Ph.D, senior scientist at Quick-Med Technologies, will deliver a podium presentation at the prestigious annual Symposium on Advanced Wound Care and Wound Healing Society combined Conference (SAWC/WHS). Dr. Liesenfeld will present “Protease Inhibitors Prevent Microvesication in Sulfur Mustard Wounds on Human Skin Explants.” This paper, coauthored with M. Mol (TNO Laboratories, Netherlands) and G. Schultz (the University of Florida at Gainesville), summarizes research that demonstrates the Company's Ilomastat technology, a powerful matrix metalloprotease inhibitor, can suppress the primary blistering damage mechanism in a human tissue explant model after exposure to sulfur mustard, even when treatment occurred hours after exposure.

Additionally, the Company has announced that two poster abstracts have been accepted for presentation:

“Persistent Skin Sanitizer with Sustained Microbicidal Properties" - W. Toreki, D. Moore, B. Liesenfeld, J. Vella, G. Schultz, J. Olderman. and R. Carr; Quick-Med Technologies and the University of Florida at Gainesville. (Blue Ribbon Category)

“Absorbent Microbicidal Wound Dressing Material with Protease Inhibition Properties" - B. Liesenfeld, G. Schultz, J. Azeke, O. Moloye, W. Toreki, D. Moore, J. Olderman and R. Carr; Quick-Med Technologies and the University of Florida at Gainesville.

This year's SAWC/WHS conference is being held in San Diego, CA from April 24 - 27.

Dr. Liesenfeld's presentation takes place on Saturday, April 26 from 3:45 - 5:45 p.m. Quick-Med Technologies' posters will be displayed on April 25 and 26 from 7:00 a.m. to 8:45 a.m.

To schedule a meeting with Dr. Liesenfeld, please contact us at (888) 835-2211 Ext 107 or email to: nsorobey@quickmedtech.com

About the SAWC/WHS
Now in its 21st year, the Symposium on Advanced of Wound Care in tandem with the Wound Healing Society Meeting (SAWC/WHS) is specifically dedicated to the wounds and wound-related issues. The largest conference of its kind drawing attendees from all over the world, the meeting is an informational hub for multidisciplinary wound care clinicians and researchers. The SAWC/WHS comprises four days of educational sessions, meetings, interactive events, and social gatherings, including a pre-and-post-conference. Visit the SAWC website for the most up-to-date information at www.sawc.net

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) is a life sciences company that is developing broad-based technologies for the healthcare and consumer markets. The Company's two core product groups under development are (1) NIMBUS®, a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products; and (2) MultiStat™ family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets. For more information, see: www.quickmedtech.com

For additional further information, please contact QMT:

CONTACT:
Natasha A. Sorobey, Investor & Media Relations
Tel. (888) 835.2211 Ext 107
Email: info@quickmedtech.com

Natasha A. Sorobey -- Corporate & Investor Relations (Canada)
Phone: (403) 203-4748
Email: nsorobey@quickmed-technologies.com

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including launch and approval of the potential products described herein and the Company¹s results of operations. The Company is also subject to other risks as detailed from time-to-time in the Company¹s SEC filings.